Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Sio Gene Therapies Inc (SIOX)

OTC Markets
Currency in USD
Disclaimer
0.478
0.000(0.00%)
Closed

SIOX Comments

This is Ready for a good run, bought for $1,13, I'm waiting for a run to the north, there are catalysts for the near future, with this breakthrough attempt it can go crazy.
time is due I see you in the double digits 😎
What floats and looks like a snickers bar?
Lol!
Whaatt
Sky is the limit
NEWS. Shelf offering .They will add most likely 10 mil. new shares. They say in new filing this will be on open market. Caution
Shares Outstanding 48,467,922 Volume today: 45,770,746 Somebody made millions selling  from $3.75 to $4.15
all green tomorrow 🔥
See you at @ $2.5 this week.
Wat happened this was blowing up
Fake and misleading news. Positive  is not "positive" Sold all at $3.6. All insiders  and  institutional holders sold above $3.75. Scam
Garbage
this should hit $4.5 today
Why is this up??
Positive data on an important clinical study
Yeah read it aftermarket but still sold my +-$8000 worth of shares before market close, bummer
Anyone watching?
New chief commercial officer appointed, things are getting really interesting
Crazy move ahead, stay tuned
Something is moving on under the radar
What’s going on with this one?
Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy. GlobeNewswire•March 11, 2019. Generally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs disease. Stable clinical condition from baseline to month 3 without deterioration on neurological exam. Increase in CSF β-Hexosaminidase A enzyme activity from baseline to month 3, surpassing the 0.5% threshold expected for a clinically important effect. Axovant to present at the Cowen and Company 39th Annual Health Care Conference on March 11th at 12:00 PM (Eastern Time). NEW YORK and BASEL, Switzerland, March 11, 2019 (GLOBE NEWSWIRE) -- Axovant (AXGT), a clinical-stage company developing innovative gene therapies,
Axovant Reports Positive Interim Results From First Cohort Of SUNRISE *****Phase 2 Trial Of AXO-Lenti *****Gene Therapy In Parkinson’s Disease
got it 1.23 sold 1.30 full moon. hahaha
damn - cant wait to sell
Good buy? Or no?
Going to the
Got it at $1.76 oh yeah baby going to the moon
Looks like you know what you're doing. can you give me advice?
short from 11.07 / 11.77
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.